PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24727234-9	2014	Furthermore, RAGE expression in mononuclear cells was significantly (p = 0.008) decreased to a greater degree in the pioglitazone group at 24 weeks (-7.39 +- 5.18 vs. -3.39 +- 5.72 MFI).	Pioglitazone	117-129	advanced glycosylation end-product specific receptor	Homo sapiens	13-17	
25307746-0	2015	Pioglitazone, a PPARgamma agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling.	Pioglitazone	0-12	advanced glycosylation end-product specific receptor	Homo sapiens	118-122	
25307746-3	2015	We hypothesized that the pathological receptor for advanced glycation end products (RAGE) is involved in the PGZ anti-tumor process.	Pioglitazone	109-112	advanced glycosylation end-product specific receptor	Homo sapiens	38-82	
25307746-3	2015	We hypothesized that the pathological receptor for advanced glycation end products (RAGE) is involved in the PGZ anti-tumor process.	Pioglitazone	109-112	advanced glycosylation end-product specific receptor	Homo sapiens	84-88	
25307746-8	2015	Moreover, PGZ inhibited proliferative activity and invasive potential, and induced apoptosis and cell cycle arrest in HCC cells resulting in increased expression of PPARgamma and decreased expression of RAGE, NF-kappaB, HMGB1, p38MAPK, Ki-67, MMP-2, and CyclinD1.	Pioglitazone	10-13	advanced glycosylation end-product specific receptor	Homo sapiens	203-207	
25307746-9	2015	Furthermore, knockdown of RAGE or NF-kappaB by siRNA effectively suppressed cell proliferation and invasion, and mediated the inhibitory effects of PGZ in HCC cells.	Pioglitazone	148-151	advanced glycosylation end-product specific receptor	Homo sapiens	26-30	
25307746-11	2015	In addition, PGZ as a PPARgamma agonist may inhibit growth and invasion of HCC cells via blockade of the RAGE signaling.	Pioglitazone	13-16	advanced glycosylation end-product specific receptor	Homo sapiens	105-109	
24727234-11	2014	CONCLUSION: Pioglitazone suppresses RAGE expression and increases circulating sRAGE/esRAGE, and those activities are not necessarily dependent on plasma glucose or insulin resistance levels.	Pioglitazone	12-24	advanced glycosylation end-product specific receptor	Homo sapiens	36-40